Mylan has announced the launch of Repaglinide Tablets, the generic version of Novo Nordisk’s Prandin.

RELATED: Endocrine Disorders Resource Center

Repaglinide is an oral meglitinide used in the management of non-insulin dependent diabetes mellitus (type 2). Repaglinide reduces blood glucose levels by stimulating the release of insulin from the pancreas and closing ATP-dependent potassium channels in the ß-cell membrane through binding at characterizable sites. As the potassium channel blockade depolarizes the ß-cell, the calcium channels are opened and the increased calcium induces insulin secretion.

Mylan’s Repaglinide Tablets are available in 0.5mg, 1mg, and 2mg strengths.

For more information call (800) RX-MYLAN or visit